PHILADELPHIA, June 13, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony ® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced the pricing of a previously announced underwritten public offering of 4,025,000 shares of its common stock, offered at a price to the public of $2.70 per share. The gross proceeds to Echo from this offering are expected to be approximately $10,867,500 before deducting the underwriting discount and other estimated offering expenses payable by Echo. Echo Therapeutics has granted the underwriters a 45-day option to purchase up to an aggregate of 603,750 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on or about June 19, 2013, subject to customary closing conditions.
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
The offering is being made pursuant to a shelf registration statement that Echo previously filed with the Securities and Exchange Commission (the "SEC") and which is effective. A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on June 7, 2013, and a final prospectus supplement and accompanying base prospectus will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and, when available, electronic copies of the final prospectus supplement, as well as the accompanying base prospectus, may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18 th Floor, New York, NY, 10019, telephone: (212) 813-1010 or email: firstname.lastname@example.org. Electronic copies of the final prospectus supplement and accompanying base prospectus will also be available on the SEC's website located at www.sec.gov.This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts